How can phage companies protect their intellectual property?

Issue 60 | January 17, 2020
13 min read
Capsid and Tail

Photo by National Cancer Institute on Unsplash

This week, we bring you an interview with Michele Wales, founder of the legal firm InHouse Patent Counsel. She tells us about the unique challenges phage companies face in protecting their IP, and why she’s optimistic about what’s to come.

Michele Wales of InHouse Patent Counsel

Michele Wales, PhD, JD is the Founder and Principal at InHouse Patent Counsel, a law firm which offers an innovative approach to in-house IP counsel for existing and start-up companies in the biotech industry.

Michele will be speaking at Kisaco Research’s Phage Futures Congress, which will be held February 5-6, 2020.

The Phage Futures Congress will bring together biotech, pharma, academia and governmental bodies to help move phage therapy forward into clinically and commercially viable therapeutics.

For a 10% discount, code enter PHAGEDIRECTORY at checkout!

Phage Futures Congress

What’s New

PhagoMed attended the Biotech Showcase 2020 this week in San Francisco, and announced it is looking to raise $16 million from US and European investors to bring its phage products to the clinic (watch this interview with CEO Alexander Belcredi).

BiotechFunding

Adaptive Phage Therapeutics was named one of five biotech companies to watch in 2020 by BioBuzz.

BiotechNews article

Hannah Hampton (University of Otago) and colleagues published a review in Nature on the arms race between bacteria and phages.

ResearchReviewPhage-host interactions

Johanna Sweere (Stanford University) and colleagues developed a mouse model of chronic Pseudomonas wound infection that does not rely on impaired immunity and lasts 10 days without causing sepsis/excessive morbidity. Advances in Wound Care article | JOVE (video version).

ResearchAnimal Model

A nice Inside Science article on the underestimated roles of viruses in chemical cycles and climate, and the research that’s amassing on the subject. Phage researchers Lindsey Solden, Gary Trubl, Jennifer Brum, Martha Clokie and more are interviewed.

News articleResearch

The 4th Phages for Global Health workshop started this week in Tanzania! The 25 participants come from Kenya, Rwanda, Tanzania and Uganda.

WorkshopGlobal Health

Save the date for Viruses of Microbes 2020, which will be hosted in Guimarães, Portugal July 13-17, 2020.

Also, students and postdocs, stay tuned: Phage Directory will be giving out travel awards!

Conference

Latest Jobs

Dr. Andrew Hryckowian is starting a new lab at the University of Wisconsin-Madison and is hiring a researcher and a research specialist. His lab will focus on the gut microbiome with specific foci on host diet, bacterial pathogens, and bacteriophages.
The University of Pretoria in South Africa is looking for a postdoc to investigate changes in phage populations in hot desert soils in response to wetting events.
Dr. Robert Czajkowski at the University of Gdansk in Poland is looking for a PhD student to study the receptors involved in the adsorption of phages to Dickeya solani and Pectobacterium parmentieri cells and the ecological cost of resistance to phages in vitro and in planta.
Dr. Wilfried Moreira’s group at the Singapore-MIT Alliance for Research and Technology Centre has put together a phage isolation, screening and engineering platform for developing phage-based technologies to target pathogens. They’re hiring a Laboratory Assistant.

Community Board

Anyone can post a message to the phage community — and it could be anything from collaboration requests, post-doc searches, sequencing help — just ask!

Second quarterly IPATH Newsletter

The Center for Innovative Phage Applications and Therapeutics (IPATH) at UCSD has published the second issue of its quarterly newsletter.

This issue describes the speaker series they hosted in 2019, which you can watch online, along with info about their upcoming phage therapy clinical trial (phase 2, cystic fibrosis, Pseudomonas aeruginosa, phages given IV and nebulized).

NewsletterPhage Therapy

How can phage companies protect their intellectual property?

Profile Image
Phage microbiologist and co-founder of Phage Directory
Co-founder
Phage Directory, Atlanta, GA, United States

Jessica Sacher is a co-founder of Phage Directory and has a Ph.D in Microbiology and Biotechnology from the University of Alberta.

For Phage Directory, she takes care of the science, writing, communications, and business aspects.

This week, we bring you a Q&A with Michele Wales, Founder and Principal at InHouse Patent Counsel.

This piece was produced in collaboration with Kisaco Research.

Jessica: It’s really exciting to meet someone who’s on the legal side who’s also familiar with phages. There’s a lot of talk in the phage field about how important protecting phage IP is for incentivizing development.

Michele: Exactly. If you aren’t able to find a way to protect and patent phage technology, then why would investors invest money? How are they going to recoup their investments?

Have you worked with companies that are trying to tackle this and protect their phage IP?

Yes, I’m outside counsel for Adaptive Phage Therapeutics. They’re one of the companies developing phage as therapeutics to treat antibiotic resistant infections.

What was your background before that?

I have a PhD in Human Genetics from Johns Hopkins Medical School, and a JD from the George Washington Law Center. Over my career, I have focused on protecting biological therapeutics, such as DNA, protein, and antibody therapeutics. I worked for 15 years with Human Genome Sciences (HGS), where I ran their intellectual property (IP) and litigation department.

HGS was acquired by GSK about 7 years ago now, and at that point instead of going to a big law firm, I chose to start my own firm, where my practice concentrates on providing legal advice to emerging companies, mainly in the biologics field. These companies are generally smaller, less than 200, and maybe even less than 50 people, and normally don’t have any outside counsel. So I become very immersed in their business plan, their strategies, and how they’re looking to license and/or develop their IP portfolio, because IP is such a critical asset for them especially at the beginning. I work hand in hand with their CEOs, senior management and often their board to develop and then implement their strategy.

I also do a lot of public speaking on gene patenting, both in the US and internationally. To me, patenting a phage raises similar issues as when one patents a human gene.

My understanding is that patenting a gene came into question because of whether a gene is a natural entity or not. Is that the reason it’s similar to phages?

Yes. Since the 80s, the US was very strong on the patenting of human sequences. HGS was the “poster child” for this issue. And then about seven years ago the Supreme Court held that the patenting of a natural polynucleotide sequence, a sequence found in nature, was not patentable subject matter. Instead, the Supreme Court held in a case referred to as “Myriad Genetics” that the characterization of a new gene is just a discovery and not an invention. This decision changed the way the industry needed to protect DNA sequences.

But even though the Supreme Court held that DNA sequences found in nature can’t be patented, there are ways to “claim around” this decision. For example, claiming a sequence with non-natural sequences, such as expression sequences, can be deemed patentable subject matter. The expression vector isn’t found in nature — now it is patentable. So even though the Supreme Court made it clear that sequences found in nature can’t be patented, there are ways to get around it. The biotech industry can still thrive and exist.

Is this a little-known fact? Does the biotech industry realize this?

I don’t think investors always realize this. I think they get very nervous when a therapeutic product involves DNA, protein or antibody sequences. And I’m often asked to explain this conceptually to investors, so I guess it’s still a question. However, it is something that biotech lawyers know.

Can you protect phages by this logic?

So protecting phage has two main problems. The first problem is that phage are completely found in nature, so unless the phage are somehow further genetically engineered, for example if a portion of the sequence is removed, or a tag of some sort is added to the phage, you’re really going to have difficulty distinguishing the “therapeutic phage” from the phage found in nature. Therefore, protecting phage isolated from nature will be hard.

The second problem is because phage evolve so quickly, that even if you are able to patent a particular phage sequence, it would be very easy for a competitor to take that sequence and modify a bunch of nucleotides, and now it’s no longer the same phage sequence that is protected by the original patent. So for phage patenting, the two big hurdles are: one, the phage are found in nature, and two, the claims can easily be designed around by a competitor to escape infringement.

How might phage companies get around these hurdles?

So if you’re a company, you need to somehow find a way to give yourself a commercial advantage over your competitors. Examples of such advantages would be to protect methods of producing the phage in a highly purified fashion, methods of storing the phage, or methods of screening the phage for activity. Currently, the ability to identify therapeutically-relevant phage as quickly as possible is one place in phage process development where companies compete. If a company develops an assay that can generate a cocktail of phage to be used to treat a patient in six hours, where your competitors are doing it in four days, that’s something you’d want to patent. And so it’s a very different paradigm than protecting therapeutic proteins. Essentially you’re protecting methods that would be generic to all phage, and not phage-specific protection. This is the approach that I believe phage companies should consider.

We’ve been talking to a number of phage biotech companies, and we were surprised when some said it’s not a big concern if they get a phage and it changes over time, because they’re not thinking about patenting the phages. But still they’ve been trying to get phages from academic labs so they can screen them. And yet academic labs are thinking they have to patent their phages so they will be attractive to companies.

It sounds like the conversations you’ve been having are very consistent with what I’ve said. What are the companies you’ve talked to thinking, when it comes to how to protect their phages?

Engineering the phages comes up a lot. And the fact that they’re saying “we don’t care so much about the phage itself”, that their bottlenecks involve finding lots of phages to screen that are different from each other, and that they talk about plans to subject the phages to downstream processes, suggests that they plan to protect the processes rather than the phages.

Yes, that’s exactly what I was saying, it’s good that we’re consistent!

Do you consider yourself targeting a niche area that others aren’t exploring? Or are other law firms starting to think about phages?

Yeah, I think I’m niche, in a sense that I was in-house counsel at a company for a long time, whereas most law firm attorneys have only law firm experience. Because I was an executive at a company, I take a much different approach to the patenting than maybe my colleagues do. We’re always looking at a patenting question from a business standpoint — for example, does this make business sense to do and/or is this where you want to spend your money? I think that law firms often focus on billable hours and therefore it’s very easy to recommend, “hey you should patent the phage sequences”. And I usually am working with companies that don’t have a lot of money, and so we need to be strategic. And I think maybe that’s a difference that I bring to the table, because I’m looking at how do we get the biggest bang for our buck — how are we going to protect these natural products?

Are you feeling optimistic about phage companies having a fighting chance? It seems like there’s so many things stacked against any biotech, let alone one dealing with phages. Or do you see this as a situation where every field has its challenges, and this is just another one?

I think you’re absolutely right. Every field has its challenges, this is just the one that phage companies have. I think when you have challenges, it spurs innovation, and maybe in the past, people may have not spent money on manufacturing or process development; in this situation it’s money well spent, and who knows what type of innovation might come from it. It may not be straightforward, but that’s always the fun of it.

This interview has been edited for clarity.

Further reading

Check out the four-part series we published last year on phage IP:

This issue was produced in collaboration with Kisaco Research. Download the PDF version on their site here!

Check out their upcoming conference, where Michele Wales will speak on phage IP issues:

The Phage Futures Congress (Feb 5-6, 2020) will bring together biotech, pharma, academia and governmental bodies to help move phage therapy forward into clinically and commercially viable therapeutics.

For a 10% discount, enter code PHAGEDIRECTORY at checkout!

Phage Futures Congress

Capsid & Tail

Follow Capsid & Tail, the periodical that reports the latest news from the phage therapy and research community.

We send Phage Alerts to the community when doctors require phages to treat their patient’s infections. If you need phages, please email us.

Supported by

Leona M. and Harry B. Helmsley Charitable Trust

Crossref Member Badge